Clinical trial NCT00918658: Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
Official title: Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Keywords: childhood chronic myelogenous leukemia
chronic myelogenous leukemia
adult acute lymphoblastic leukemia
childhood acute lymphoblastic leukemia
adult acute myeloid leukemia
childhood acute myeloid leukemia/other myeloid malignancies
multiple myeloma
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2009-06-11
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer.

PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.

Detailed description: OBJECTIVES:

* To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays.
* To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry.

OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Meets one of the following criteria:

  * No evidence of malignancy
  * Diagnosis of one of the following:

    * Acute myeloid leukemia
    * Acute lymphoblastic leukemia
    * Chronic myelogenous leukemia
    * Multiple myeloma

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Collection of normal and malignant cells to use as target cells in cytotoxicity assays
timeFrame: We anticipate collecting approximately 30 samples in total, over a 1-2 year period.
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
name: Rose Beck, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: